Blueprint Medicines Announces European Commission Approval of AYVAKYT(R) (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors

CAMBRIDGE, Mass., Sept. 25, 2020 -- (Healthcare Sales & Marketing Network) -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that ... Biopharmaceuticals, Regulatory Blueprint Medicines, AYVAKIT, avapritinib, gastrointestinal stromal tumor
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news